- Home
- FSEA vs CALC Comparison
FSEA vs CALC Comparison
Compare FSEA & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSEA
- CALC
- Stock Information
- Founded
- FSEA 1890
- CALC 2011
- Country
- FSEA United States
- CALC United States
- Employees
- FSEA N/A
- CALC N/A
- Industry
- FSEA Savings Institutions
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- FSEA Finance
- CALC Health Care
- Exchange
- FSEA Nasdaq
- CALC Nasdaq
- Market Cap
- FSEA 53.7M
- CALC 48.1M
- IPO Year
- FSEA N/A
- CALC N/A
- Fundamental
- Price
- FSEA $11.65
- CALC $3.09
- Analyst Decision
- FSEA
- CALC Strong Buy
- Analyst Count
- FSEA 0
- CALC 2
- Target Price
- FSEA N/A
- CALC $14.50
- AVG Volume (30 Days)
- FSEA 3.2K
- CALC 53.0K
- Earning Date
- FSEA 11-07-2025
- CALC 08-12-2025
- Dividend Yield
- FSEA N/A
- CALC N/A
- EPS Growth
- FSEA N/A
- CALC N/A
- EPS
- FSEA N/A
- CALC N/A
- Revenue
- FSEA $14,095,000.00
- CALC N/A
- Revenue This Year
- FSEA N/A
- CALC N/A
- Revenue Next Year
- FSEA N/A
- CALC N/A
- P/E Ratio
- FSEA N/A
- CALC N/A
- Revenue Growth
- FSEA 30.26
- CALC N/A
- 52 Week Low
- FSEA $8.90
- CALC $1.42
- 52 Week High
- FSEA $11.95
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- FSEA 56.63
- CALC 56.35
- Support Level
- FSEA $11.43
- CALC $3.04
- Resistance Level
- FSEA $11.95
- CALC $3.38
- Average True Range (ATR)
- FSEA 0.14
- CALC 0.24
- MACD
- FSEA 0.01
- CALC 0.02
- Stochastic Oscillator
- FSEA 50.00
- CALC 58.57
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.